Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vatrix Medical Inc.

This article was originally published in Start Up

Executive Summary

Early detection of abdominal aortic aneurysms - which are associated with degradation of the artery and result in weakening and expansion of the blood vessel that can lead to an often-fatal rupture - appears promising with a simple urine test being developed by Vatrix Medical Inc. The start-up is also introducing a minimally invasive endovascular procedure to slow AAA growth by treating the aneurysmal tissue with a novel class of stabilizing agents that bind directly to the diseased artery.
Advertisement

Related Content

EVAR Market: Challenges, Innovation and Growth
EVAR Market: Challenges, Innovation and Growth
EVAR Market: Challenges, Innovation and Growth
EVAR Market: Challenges, Innovation and Growth
Start-Up Previews (03/2010)
Start-Up Previews (03/2010)
In Search of the Perfect Aortic Endograft

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT037665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel